SlideShare uma empresa Scribd logo
1 de 22
Inherited Bleeding Disorder Comprehensive
Care Centres / Standards of Care
Impact on Quality of Care and Health
Outcomes
David Page
National Executive Director
Canadian Hemophilia Society
CORD Rare Disease Day Conference
March 5, 2015
Inherited bleeding disorders
Bleeding disorder
Number registered in
centres*
Incidence
Hemophilia A 3094 1 in 10,000
Hemophilia B 869 1 in 40,000
Von Willebrand disease 4184 1 in 1000?
Rare factor
deficiencies (I, II, V, VII,
X, XI, XIII)
1517
1 in 100,000 to 1 in
5,000,000
Platelet function
disorders
954 Very low
* Data from 2013-14 CHS centre resource assessment
Inherited bleeding disorders
Severity of
bleeding
symptoms
Hemophilia A
and B
von Willebrand
disease
Rare factor
deficiencies
Platelet
function
disorders
Joints ✓✓✓
Muscles ✓✓ ✓
Bruising ✓ ✓ ✓✓ ✓
Vital organs ✓✓ ✓✓✓
Mucosal ✓ ✓✓✓ ✓ ✓✓✓
Menorrhagia ✓ ✓✓✓ ✓ ✓✓
Post-trauma ✓ ✓ ✓✓✓ ✓
Surgical ✓ ✓ ✓✓ ✓
Lacerations ✓✓ ✓ ✓✓
Comprehensive care centres
5 pediatric centres
5 adult centres
15 combined ped-adult centres
Comprehensive care
Hemophilia Care
 
“Medical care for hemophilia is specialized. A person
with hemophilia must receive care from healthcare
workers who have expert knowledge of the bleeding
disorder. The wide-ranging needs of people with
hemophilia and their families are best met through
Hemophilia Treatment Centres rather than by
individual doctors.”
- World Federation of Hemophilia: Organizing a
National Programme for Comprehensive Hemophilia
Care.
Comprehensive care
Hemophilia Care
 
“Medical care for hemophilia is specialized. A person
with hemophilia must receive care from healthcare
workers who have expert knowledge of the bleeding
disorder. The wide-ranging needs of people with
hemophilia and their families are best met through
Hemophilia Treatment Centres rather than by
individual doctors.”
- World Federation of Hemophilia: Organizing a
National Programme for Comprehensive Hemophilia
Care.
Comprehensive care principles*
• Improved quality of life
• Collaboration among HTCs and networks needs to be
encouraged
• Bleeding disorders are associated with a number of
complications… and so care needs to be comprehensive.
• Evaluation of clinical outcomes is essential.
• Standards of care are needed and should be audited.
• Accountability for utilization of coagulation therapy is
necessary
• Regional differences within the province or region must be
acknowledged in the provision of care.
* CANADIAN COMPREHENSIVE CARE STANDARDS FOR HEMOPHILIA AND OTHER
INHERITED BLEEDING DISORDERS, First Edition, June 2007
Health outcomes
“A two-year study of 40 children in Montreal indicates
that home care treatment of bleeding episodes,
supported by a comprehensive care centre, reduces
hospitalizations by 85%, arrests the development of
severe hemorrhages and reduces costs by 85%.”
Health outcomes
“A two-year study of 40 children in Montreal indicates
that home care treatment of bleeding episodes,
supported by a comprehensive care centre, reduces
hospitalizations by 85%, arrests the development of
severe hemorrhages and reduces costs by 85%.”
(Dr. Hanna Strawczynski, MD of Canada, October
1972)
Health outcomes
“Patients who used both home therapy and received
care in HTCs* had the highest probability of avoiding
hospitalization for bleeding complications during the
follow-up period.”
J. M. SOUCIE et al, Haemophilia (2001), 7, 198±206
“Those persons who had received care in an HTC had
a 40 percent decreased risk of morbidity and
mortality.”
J.M. Soucie et al, BLOOD, 15 July 2000 • Volume 96, Number 2
*HTC – Hemophilia Treatment Centre
Comprehensive care
1. Provincial designation
2. National patient registries
3. Self/family administration of therapeutics
4. Patient, family and association involvement in care
5. Education of patients, families and health care
providers
6. Standards of care and portability
7. Decentralization through outreach
(Adopted by Network of Rare Blood Disorder
Organizations, 2006 conference)
Comprehensive care
8. Inter-disciplinary care
9. Defined core services delivered by a
comprehensive care team
10. Program evaluation and accreditation
11. National collaboration
12. Post-marketing surveillance
13. Collaborative research
14. Flexibility in organization
(Adopted by Network of Rare Blood Disorder
Organizations, 2006 conference)
Hemophilia/IBD standards of care
Adopted in June 2007 after interdisciplinary study
by…
Association of Hemophilia Clinic Directors of Canada
Canadian Association of Nurses in Hemophilia Care
Canadian Physiotherapists in Hemophilia Care
Canadian Social Workers in Hemophilia Care
Canadian Hemophilia Society (patient organization)
Standards of care document
• Principles of care
• Populations served
• Definition of core team members (MD, RN, PT, SW,
admin/data)
• Definition of extended team members (e.g. OB-
GYN)
• Services provided
• Responsibilities of an HTC
• Standards
• Scope of care & key indicators
• e.g Establish and maintain a full complement of core team
members
• Quality measures & key indicators
• e.g. Participate in data collection
• Therapeutic services & key indicators
• E.g. Have sufficient number of assessment clinics
Assessing standards of care
2007: Standards adopted
2009: Self-assessment of standards by 22 of 24 HTCs
2009: Standards found to be realistic, useful,
acceptability judged high, and appropriate to be used
for external accreditation (audit)
2010: External audit process developed based on
similar process used by HTC networks in U.K.
and Ireland
2011-2012: Audit process delayed by hospital patient
privacy issues
2013: CHS developed own “centre assessment”
process based on work done by its Quebec
Chapter
Centre assessments
In three parts:
1.In-person interviews with all core team members in
24/25 centres across Canada (approximately 150
people) to assess their capacity to respect standards
of care
2.Data collection on numbers of patients and FTEs of
core team members
3.In-depth, anonymous patient satisfaction survey
sent to a random sample of patients (400 responses)
Centre assessments: deliverables
20 individual centre assessments (plus a collective
assessment for 4 Quebec centres) with…
• HTC strengths
• HTC weaknesses
• Assessments of human resource needs
• Assessments of physical resource needs
• Patient observations and appreciation
• Recommendations to HTCs, hospitals and
Ministries of Health
Centre assessments: key observations
• Most centres have insufficient human resources to
respect standards
• Many centres have insufficient physical resources
(space and time) to properly conduct clinics
• Core teams are not complete in some centres (e.g.
no dedicated physiotherapist or social worker)
• Many centres do not have adequate resources to
collect and act on health outcome and factor
utilization information
• Patients are overwhelmingly appreciative of the
services and care they receive!
Centre assessments: deliverables
A national report (to be published in June 2015)
including…
•Common strengths
•Common weaknesses
•Recommendations that apply across Canada
•Data:
• Ratios of FTEs in each centre by discipline per
100 patients with hemophilia A and B
• Comparison of the cost of coagulation
therapies to the cost of delivery of care
(staffing, procedures, hospital admissions, lab
work…)
Centre assessments: advocacy
• Delivery of final centre assessment reports to
centre staff and provincial chapters of CHS (✔)
• Meetings with local chapters and centre staff to
develop local advocacy plans
• Meetings with local and provincial health officials,
where needed
• Meeting with Provincial / Territorial Blood Liaison
Committee
The concept of comprehensive care for inherited
bleeding disorders, based on standards of care, is
accepted and widely adopted in developed and
developing countries around the world …
… and is waiting to be widely copied by other rare
disorders!

Mais conteúdo relacionado

Mais procurados

Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Canadian Organization for Rare Disorders
 

Mais procurados (20)

Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
 
RWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs WebinarRWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs Webinar
 
IRDiRC: progress and expectations
IRDiRC: progress and expectationsIRDiRC: progress and expectations
IRDiRC: progress and expectations
 
Patient Centered Health Care Advocacy
Patient Centered Health Care AdvocacyPatient Centered Health Care Advocacy
Patient Centered Health Care Advocacy
 
Michael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation finalMichael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation final
 
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
 
CORD Rare Disease Patient Survey
CORD Rare Disease Patient SurveyCORD Rare Disease Patient Survey
CORD Rare Disease Patient Survey
 
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
 
Cathy parker the orphan drug framework
Cathy parker the orphan drug frameworkCathy parker the orphan drug framework
Cathy parker the orphan drug framework
 
Glenn Monteith expert patients forum
Glenn Monteith  expert patients forumGlenn Monteith  expert patients forum
Glenn Monteith expert patients forum
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
 
A Brief History of the CDFI
A Brief History of the CDFIA Brief History of the CDFI
A Brief History of the CDFI
 
Durhane: Rare Drug Strategy Webinar
Durhane: Rare Drug Strategy WebinarDurhane: Rare Drug Strategy Webinar
Durhane: Rare Drug Strategy Webinar
 
Patient Group Development and Engagement
Patient Group Development and EngagementPatient Group Development and Engagement
Patient Group Development and Engagement
 
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
 
Webinar: Learnings and Unresolved Issues
Webinar: Learnings and Unresolved IssuesWebinar: Learnings and Unresolved Issues
Webinar: Learnings and Unresolved Issues
 
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
Advances in Rare Disease Gareth Baynam, Western Australia Health Department (...
 
Rare disease studies and the digital opportunity Exom Group (SEPT 2017)
Rare disease studies and the digital opportunity Exom Group (SEPT 2017)Rare disease studies and the digital opportunity Exom Group (SEPT 2017)
Rare disease studies and the digital opportunity Exom Group (SEPT 2017)
 
Dr. Greenberg CORD Mar 23-24, 2022 Rare Drug Strategy WebinarDay
Dr. Greenberg CORD Mar 23-24, 2022 Rare Drug Strategy WebinarDayDr. Greenberg CORD Mar 23-24, 2022 Rare Drug Strategy WebinarDay
Dr. Greenberg CORD Mar 23-24, 2022 Rare Drug Strategy WebinarDay
 

Semelhante a David page cord standards of care 05 03-2015

International Health Policy and Practice: Comparing the U.S. and Canada on Ef...
International Health Policy and Practice: Comparing the U.S. and Canada on Ef...International Health Policy and Practice: Comparing the U.S. and Canada on Ef...
International Health Policy and Practice: Comparing the U.S. and Canada on Ef...
The Commonwealth Fund
 
appendix-4--powerpoint-presentation-single-unit-transfusion.pdf
appendix-4--powerpoint-presentation-single-unit-transfusion.pdfappendix-4--powerpoint-presentation-single-unit-transfusion.pdf
appendix-4--powerpoint-presentation-single-unit-transfusion.pdf
htpplqzyafxxsptfln
 
Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...
Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...
Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...
Huron Consulting Group
 

Semelhante a David page cord standards of care 05 03-2015 (20)

Driving progress in healthcare through NHS research
Driving progress in healthcare through NHS researchDriving progress in healthcare through NHS research
Driving progress in healthcare through NHS research
 
STREAM ONE- David Page Best Practice Case: Hemophilia -
STREAM ONE- David Page Best Practice Case: Hemophilia -STREAM ONE- David Page Best Practice Case: Hemophilia -
STREAM ONE- David Page Best Practice Case: Hemophilia -
 
David Page: Rare Disease Day 2016 Conference
David Page:  Rare Disease Day 2016 Conference David Page:  Rare Disease Day 2016 Conference
David Page: Rare Disease Day 2016 Conference
 
powerpoint-presentation-Multi-verse tecto.pdf
powerpoint-presentation-Multi-verse tecto.pdfpowerpoint-presentation-Multi-verse tecto.pdf
powerpoint-presentation-Multi-verse tecto.pdf
 
Cadth 2015 b7 symposium cost guidance talk draft-ab_v1.0
Cadth 2015 b7 symposium cost guidance talk   draft-ab_v1.0Cadth 2015 b7 symposium cost guidance talk   draft-ab_v1.0
Cadth 2015 b7 symposium cost guidance talk draft-ab_v1.0
 
Leveraging Data And Strong Partnerships To Thrive In The Land Between Volume ...
Leveraging Data And Strong Partnerships To Thrive In The Land Between Volume ...Leveraging Data And Strong Partnerships To Thrive In The Land Between Volume ...
Leveraging Data And Strong Partnerships To Thrive In The Land Between Volume ...
 
International Health Policy and Practice: Comparing the U.S. and Canada on Ef...
International Health Policy and Practice: Comparing the U.S. and Canada on Ef...International Health Policy and Practice: Comparing the U.S. and Canada on Ef...
International Health Policy and Practice: Comparing the U.S. and Canada on Ef...
 
Moving towards value based funding
Moving towards value based fundingMoving towards value based funding
Moving towards value based funding
 
Ciliopathy Alliance 5th Anniversary Mtg - 19 Oct 2015 - National Ciliopathies...
Ciliopathy Alliance 5th Anniversary Mtg - 19 Oct 2015 - National Ciliopathies...Ciliopathy Alliance 5th Anniversary Mtg - 19 Oct 2015 - National Ciliopathies...
Ciliopathy Alliance 5th Anniversary Mtg - 19 Oct 2015 - National Ciliopathies...
 
Brian Griffin
Brian GriffinBrian Griffin
Brian Griffin
 
appendix-4--powerpoint-presentation-single-unit-transfusion.pdf
appendix-4--powerpoint-presentation-single-unit-transfusion.pdfappendix-4--powerpoint-presentation-single-unit-transfusion.pdf
appendix-4--powerpoint-presentation-single-unit-transfusion.pdf
 
International Health Policy and Practice: Comparing the U.S. and Canada on Ac...
International Health Policy and Practice: Comparing the U.S. and Canada on Ac...International Health Policy and Practice: Comparing the U.S. and Canada on Ac...
International Health Policy and Practice: Comparing the U.S. and Canada on Ac...
 
Public Reporting as a Catalyst for Better Consumer Decisions
Public Reporting as a Catalyst for Better Consumer DecisionsPublic Reporting as a Catalyst for Better Consumer Decisions
Public Reporting as a Catalyst for Better Consumer Decisions
 
Aine Carroll, National Director of Clinical Strategy & Programmes, HSE
Aine Carroll, National Director of Clinical Strategy & Programmes, HSEAine Carroll, National Director of Clinical Strategy & Programmes, HSE
Aine Carroll, National Director of Clinical Strategy & Programmes, HSE
 
Home Dialysis RA 2017
Home Dialysis RA 2017Home Dialysis RA 2017
Home Dialysis RA 2017
 
Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...
Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...
Clinical Transformation: Fundamentally Changing Clinical Processes to Achieve...
 
UTI collaborative 28th June 2018 presentations
UTI collaborative 28th June 2018  presentations   UTI collaborative 28th June 2018  presentations
UTI collaborative 28th June 2018 presentations
 
QI initiative: Acute Kidney Injury (AKI) Care in Acute Oncology
QI initiative: Acute Kidney Injury (AKI) Care in Acute OncologyQI initiative: Acute Kidney Injury (AKI) Care in Acute Oncology
QI initiative: Acute Kidney Injury (AKI) Care in Acute Oncology
 
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
 
Developing and implementing clinical standards for seven day services
Developing and implementing clinical standards for seven day servicesDeveloping and implementing clinical standards for seven day services
Developing and implementing clinical standards for seven day services
 

Mais de Canadian Organization for Rare Disorders

Mais de Canadian Organization for Rare Disorders (20)

Webinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
Webinar: Investing $1.5b in A Sustainable Rare Disease EcosystemWebinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
Webinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
 
CORD-RQMO: English Slides
CORD-RQMO: English Slides CORD-RQMO: English Slides
CORD-RQMO: English Slides
 
CORD-RQMO: French Slides
CORD-RQMO: French SlidesCORD-RQMO: French Slides
CORD-RQMO: French Slides
 
Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases
Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases
Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases
 
Day 1: NORD Centres of Excellence - Pamela Gavin
Day 1: NORD Centres of Excellence - Pamela GavinDay 1: NORD Centres of Excellence - Pamela Gavin
Day 1: NORD Centres of Excellence - Pamela Gavin
 
Day 1: IAM RARE: Pamela Gavin, NORD
Day 1: IAM RARE: Pamela Gavin, NORDDay 1: IAM RARE: Pamela Gavin, NORD
Day 1: IAM RARE: Pamela Gavin, NORD
 
Day 2: Rare Disease & Drug Access Pathway
Day 2: Rare Disease  & Drug Access Pathway Day 2: Rare Disease  & Drug Access Pathway
Day 2: Rare Disease & Drug Access Pathway
 
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research NetworkDay 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
 
Dar 2: Patient Engagement and Patient Empowerment Panel
Dar 2: Patient Engagement and Patient Empowerment Panel Dar 2: Patient Engagement and Patient Empowerment Panel
Dar 2: Patient Engagement and Patient Empowerment Panel
 
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of ManitobaDay 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
 
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
 
Day 1: Newborn Screening: Pranesh Chakraborty, University of Ottawa
Day 1: Newborn Screening: Pranesh Chakraborty, University of OttawaDay 1: Newborn Screening: Pranesh Chakraborty, University of Ottawa
Day 1: Newborn Screening: Pranesh Chakraborty, University of Ottawa
 
Day 1: Phenotypes: Orion Buske, PhenoTips
Day 1: Phenotypes: Orion Buske, PhenoTipsDay 1: Phenotypes: Orion Buske, PhenoTips
Day 1: Phenotypes: Orion Buske, PhenoTips
 
Day 1: Genomic Sequencing: Kym Boycott, CHEO
Day 1: Genomic Sequencing: Kym Boycott, CHEODay 1: Genomic Sequencing: Kym Boycott, CHEO
Day 1: Genomic Sequencing: Kym Boycott, CHEO
 
Day 1: INFORM RARE
Day 1: INFORM RAREDay 1: INFORM RARE
Day 1: INFORM RARE
 
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
 
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
 
Day 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
Day 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDISDay 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
Day 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
 
Day 1: Children's Healthcare Canada CORD
Day 1: Children's Healthcare Canada CORD Day 1: Children's Healthcare Canada CORD
Day 1: Children's Healthcare Canada CORD
 
Day 1: Network of Centres of Excellence
Day 1:  Network of Centres of ExcellenceDay 1:  Network of Centres of Excellence
Day 1: Network of Centres of Excellence
 

David page cord standards of care 05 03-2015

  • 1. Inherited Bleeding Disorder Comprehensive Care Centres / Standards of Care Impact on Quality of Care and Health Outcomes David Page National Executive Director Canadian Hemophilia Society CORD Rare Disease Day Conference March 5, 2015
  • 2. Inherited bleeding disorders Bleeding disorder Number registered in centres* Incidence Hemophilia A 3094 1 in 10,000 Hemophilia B 869 1 in 40,000 Von Willebrand disease 4184 1 in 1000? Rare factor deficiencies (I, II, V, VII, X, XI, XIII) 1517 1 in 100,000 to 1 in 5,000,000 Platelet function disorders 954 Very low * Data from 2013-14 CHS centre resource assessment
  • 3. Inherited bleeding disorders Severity of bleeding symptoms Hemophilia A and B von Willebrand disease Rare factor deficiencies Platelet function disorders Joints ✓✓✓ Muscles ✓✓ ✓ Bruising ✓ ✓ ✓✓ ✓ Vital organs ✓✓ ✓✓✓ Mucosal ✓ ✓✓✓ ✓ ✓✓✓ Menorrhagia ✓ ✓✓✓ ✓ ✓✓ Post-trauma ✓ ✓ ✓✓✓ ✓ Surgical ✓ ✓ ✓✓ ✓ Lacerations ✓✓ ✓ ✓✓
  • 4.
  • 5. Comprehensive care centres 5 pediatric centres 5 adult centres 15 combined ped-adult centres
  • 6. Comprehensive care Hemophilia Care   “Medical care for hemophilia is specialized. A person with hemophilia must receive care from healthcare workers who have expert knowledge of the bleeding disorder. The wide-ranging needs of people with hemophilia and their families are best met through Hemophilia Treatment Centres rather than by individual doctors.” - World Federation of Hemophilia: Organizing a National Programme for Comprehensive Hemophilia Care.
  • 7. Comprehensive care Hemophilia Care   “Medical care for hemophilia is specialized. A person with hemophilia must receive care from healthcare workers who have expert knowledge of the bleeding disorder. The wide-ranging needs of people with hemophilia and their families are best met through Hemophilia Treatment Centres rather than by individual doctors.” - World Federation of Hemophilia: Organizing a National Programme for Comprehensive Hemophilia Care.
  • 8. Comprehensive care principles* • Improved quality of life • Collaboration among HTCs and networks needs to be encouraged • Bleeding disorders are associated with a number of complications… and so care needs to be comprehensive. • Evaluation of clinical outcomes is essential. • Standards of care are needed and should be audited. • Accountability for utilization of coagulation therapy is necessary • Regional differences within the province or region must be acknowledged in the provision of care. * CANADIAN COMPREHENSIVE CARE STANDARDS FOR HEMOPHILIA AND OTHER INHERITED BLEEDING DISORDERS, First Edition, June 2007
  • 9. Health outcomes “A two-year study of 40 children in Montreal indicates that home care treatment of bleeding episodes, supported by a comprehensive care centre, reduces hospitalizations by 85%, arrests the development of severe hemorrhages and reduces costs by 85%.”
  • 10. Health outcomes “A two-year study of 40 children in Montreal indicates that home care treatment of bleeding episodes, supported by a comprehensive care centre, reduces hospitalizations by 85%, arrests the development of severe hemorrhages and reduces costs by 85%.” (Dr. Hanna Strawczynski, MD of Canada, October 1972)
  • 11. Health outcomes “Patients who used both home therapy and received care in HTCs* had the highest probability of avoiding hospitalization for bleeding complications during the follow-up period.” J. M. SOUCIE et al, Haemophilia (2001), 7, 198±206 “Those persons who had received care in an HTC had a 40 percent decreased risk of morbidity and mortality.” J.M. Soucie et al, BLOOD, 15 July 2000 • Volume 96, Number 2 *HTC – Hemophilia Treatment Centre
  • 12. Comprehensive care 1. Provincial designation 2. National patient registries 3. Self/family administration of therapeutics 4. Patient, family and association involvement in care 5. Education of patients, families and health care providers 6. Standards of care and portability 7. Decentralization through outreach (Adopted by Network of Rare Blood Disorder Organizations, 2006 conference)
  • 13. Comprehensive care 8. Inter-disciplinary care 9. Defined core services delivered by a comprehensive care team 10. Program evaluation and accreditation 11. National collaboration 12. Post-marketing surveillance 13. Collaborative research 14. Flexibility in organization (Adopted by Network of Rare Blood Disorder Organizations, 2006 conference)
  • 14. Hemophilia/IBD standards of care Adopted in June 2007 after interdisciplinary study by… Association of Hemophilia Clinic Directors of Canada Canadian Association of Nurses in Hemophilia Care Canadian Physiotherapists in Hemophilia Care Canadian Social Workers in Hemophilia Care Canadian Hemophilia Society (patient organization)
  • 15. Standards of care document • Principles of care • Populations served • Definition of core team members (MD, RN, PT, SW, admin/data) • Definition of extended team members (e.g. OB- GYN) • Services provided • Responsibilities of an HTC • Standards • Scope of care & key indicators • e.g Establish and maintain a full complement of core team members • Quality measures & key indicators • e.g. Participate in data collection • Therapeutic services & key indicators • E.g. Have sufficient number of assessment clinics
  • 16. Assessing standards of care 2007: Standards adopted 2009: Self-assessment of standards by 22 of 24 HTCs 2009: Standards found to be realistic, useful, acceptability judged high, and appropriate to be used for external accreditation (audit) 2010: External audit process developed based on similar process used by HTC networks in U.K. and Ireland 2011-2012: Audit process delayed by hospital patient privacy issues 2013: CHS developed own “centre assessment” process based on work done by its Quebec Chapter
  • 17. Centre assessments In three parts: 1.In-person interviews with all core team members in 24/25 centres across Canada (approximately 150 people) to assess their capacity to respect standards of care 2.Data collection on numbers of patients and FTEs of core team members 3.In-depth, anonymous patient satisfaction survey sent to a random sample of patients (400 responses)
  • 18. Centre assessments: deliverables 20 individual centre assessments (plus a collective assessment for 4 Quebec centres) with… • HTC strengths • HTC weaknesses • Assessments of human resource needs • Assessments of physical resource needs • Patient observations and appreciation • Recommendations to HTCs, hospitals and Ministries of Health
  • 19. Centre assessments: key observations • Most centres have insufficient human resources to respect standards • Many centres have insufficient physical resources (space and time) to properly conduct clinics • Core teams are not complete in some centres (e.g. no dedicated physiotherapist or social worker) • Many centres do not have adequate resources to collect and act on health outcome and factor utilization information • Patients are overwhelmingly appreciative of the services and care they receive!
  • 20. Centre assessments: deliverables A national report (to be published in June 2015) including… •Common strengths •Common weaknesses •Recommendations that apply across Canada •Data: • Ratios of FTEs in each centre by discipline per 100 patients with hemophilia A and B • Comparison of the cost of coagulation therapies to the cost of delivery of care (staffing, procedures, hospital admissions, lab work…)
  • 21. Centre assessments: advocacy • Delivery of final centre assessment reports to centre staff and provincial chapters of CHS (✔) • Meetings with local chapters and centre staff to develop local advocacy plans • Meetings with local and provincial health officials, where needed • Meeting with Provincial / Territorial Blood Liaison Committee
  • 22. The concept of comprehensive care for inherited bleeding disorders, based on standards of care, is accepted and widely adopted in developed and developing countries around the world … … and is waiting to be widely copied by other rare disorders!